# Shaperon

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shaperon

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.shaperon.com
- Total disclosed funding: $43M
- Latest round: Series C (Oct 17, 2020)
- Investors on record: 11

## About

Shaperon Inc., based in South Korea, is a clinical-stage biotechnology company focused on developing innovative inflammasome inhibitors and Nanobody therapeutics for immune-mediated inflammatory disorders.Founded in 2008 and headquartered in Seoul, South Korea, Shaperon is dedicated to the development of novel therapies for inflammation-related conditions. The company's CEO, Sy ???, leads its efforts in biotechnology. On June 12, 2024, Shaperon raised KRW 12.7 billion in an IPO, marking a significant milestone in its funding journey. The total amount raised by the company amounts to KRW 13.735 billion through five investment deals.Shaperon specializes in crafting advanced inflammasome inhibitors and Nanobody therapeutics, with key products including NuGel®, NuSepin®, Oral HY209, Saviximab®, and Papiliximab®. These therapeutics address immune-mediated inflammatory disorders where existing treatments are inadequate, targeting healthcare providers, pharmaceutical companies, and research institutions across North America, Europe, and parts of Asia.In 2024, Shaperon reported revenues of KRW 12,989.4 mn, alongside an EBITDA of KRW -10,231.76 mn. The company's revenue is primarily generated through collaborations and licensing agreements with biotech firms and sales to healthcare providers, focusing on B2B transactions.Looking ahead, Shaperon plans to utilize the KRW 12.7 billion raised in its latest funding round to drive the development of new products and expand into untapped markets. The company aims to launch additional therapeutics by late 2025, with specific targets for growth in North America and Europe, leveraging its innovative portfolio to enhance its market presence.

## Funding rounds

- Series C, Oct 17, 2020, $23M — Seoul Investment Partners, Yuanta Investment, Smilegate Investment, Moorim Capital, Posco Investment, Albatross Investment, BNK Venture Capital, JX Partners
- Series B, Jun 16, 2018, $17M — SL Investment, Yuanta Investment, Smilegate Investment, NHN Investment, IBK Capital
- Series A, Feb 6, 2016, $2.9M — Yuanta Investment

## Investors

- Yuanta Investment (https://capitalatlas.ai/funds/yuanta-investment) — Series A, Series B, Series C
- SL Investment (https://capitalatlas.ai/funds/sl-investment) — Series B
- Smilegate Investment (https://capitalatlas.ai/funds/smilegate-investment) — Series B, Series C
- NHN Investment (https://capitalatlas.ai/funds/nhn-investment) — Series B
- IBK Capital (https://capitalatlas.ai/funds/ibk-capital) — Series B
- Seoul Investment Partners (https://capitalatlas.ai/funds/seoul-investment-partners) — Series C
- Moorim Capital — Series C
- Posco Investment (https://capitalatlas.ai/funds/posco-investment) — Series C
- Albatross Investment (https://capitalatlas.ai/funds/albatross-investment) — Series C
- BNK Venture Capital (https://capitalatlas.ai/funds/bnk-venture-capital) — Series C
- JX Partners (https://capitalatlas.ai/funds/jx-partners) — Series C